Grufity logoGrufity logo
StocksFundsSearch Filings

Urogen Pharma Ltd Stock Research

URGN

11.43USD-0.08(-0.70%)Market Closed

Market Summary

USD11.43-0.08
Market Closed
-0.70%

URGN Stock Price

URGN RSI Chart

URGN Valuation

Market Cap

267.5M

Price/Earnings (Trailing)

-2.4

Price/Sales (Trailing)

3.93

EV/EBITDA

-2.11

Price/Free Cashflow

-2.98

URGN Price/Sales (Trailing)

URGN Profitability

Operating Margin

88.82%

EBT Margin

-171.63%

Return on Equity

172.81%

Return on Assets

-85.13%

Free Cashflow Yield

-33.51%

URGN Fundamentals

URGN Revenue

Revenue (TTM)

68.0M

URGN Earnings

Earnings (TTM)

-111.6M

Earnings Y/Y

-6.41%

Earnings Q/Q

-4.66%

Price Action

52 Week Range

4.8516.11
(Low)(High)

Last 7 days

-2.7%

Last 30 days

13.8%

Last 90 days

15.7%

Trailing 12 Months

107.4%

URGN Financial Health

Current Ratio

6.4

URGN Investor Care

Shares Dilution (1Y)

3.16%

Peers (Alternatives to Urogen Pharma)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
326.1B
1.6B
-7.40% 77.06%
-170.12
209.44
77.54% 1.62%
285.4B
56.7B
-12.25% -1.83%
24.12
4.92
0.03% -39.22%
87.6B
12.4B
-6.52% 9.77%
20.2
7.2
-25.07% -47.28%
85.9B
9.2B
0.73% 24.28%
26.35
9.33
15.86% 32.99%
23.8B
1.0B
-8.34% 48.04%
-22.38
22.97
22.88% -19.27%
13.7B
975.7M
14.79% 105.15%
-12.27
14.02
27.41% -212.78%
10.1B
2.0B
-6.31% 2.88%
13.88
5.1
12.05% 52.86%
MID-CAP
5.2B
504.0K
-7.03% 326.29%
-16.39
2.5K
-66.53% -27.52%
3.6B
363.3M
21.73% 7.26%
-5.1
9.93
3.39% -55.81%
3.5B
204.6M
19.27% 2.79%
-6.08
17.28
-7.52% 10.65%
2.7B
18.9M
7.20% -28.12%
-3.61
140.65
- -16.17%
SMALL-CAP
3.7B
-
1.75% -2.11%
-8.59
39.11
34.30% -67.22%
1.3B
256.5M
-26.70% 74.57%
12.87
4.99
66.85% 120.61%
348.8M
165.3M
-18.85% 42.42%
-3.82
2.11
130.70% 57.97%
46.0M
881.7K
23.42% 3374.52%
-0.91
19.11
-77.61% -29.84%

Financials for Urogen Pharma

Income Statement (Last 12 Months)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue5.6%67,985,00064,357,00062,439,00057,693,00054,121,000
Gross Profit5.1%59,591,00056,703,00055,459,00051,489,00048,336,000
  S&GA Expenses3.8%86,012,00082,838,00082,622,00085,175,00086,646,000
  R&D Expenses-0.4%52,708,00052,906,00051,511,00050,341,00049,825,000
EBITDA4.6%-106,350,000-111,421,000-110,703,000--
EBITDA Margin11.8%-1.70-1.93-2.05--
Earnings Before Taxes-2.0%-110,153,000-108,028,000-107,163,000-112,252,000-111,503,000
EBT Margin11.8%-1.72-1.95-2.06--
Net Income-1.7%-111,604,000-109,783,000-109,366,000-113,746,000-113,277,000
Net Income Margin11.2%-1.75-1.97-2.09--
Free Cahsflow1.0%-86,320,000-87,225,000-81,977,000--
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets-16.7%113136128146166
  Current Assets-25.5%96.00129122140161
    Cash Equivalents-34.1%37.0055.0029.0081.00105
  Inventory26.4%5.004.005.005.005.00
  Net PPE-15.0%1.001.002.002.002.00
Liabilities2.0%230225192187183
  Current Liabilities5.5%25.0024.0019.0018.0019.00
    LT Debt, Non Current0.4%98.0098.0072.0071.0071.00
Shareholder's Equity-30.4%-116-89.36-17.07--
  Retained Earnings-5.2%-607-577-548-522-495
  Additional Paid-In Capital0.6%491488485481479
Accumulated Depreciation8.9%3.003.002.00--
Shares Outstanding1.3%23.0023.0023.0023.0023.00
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations-2.1%-89,370-87,559-85,877-86,741-81,487
  Share Based Compensation-6.3%9,91710,58013,56916,64419,867
Cashflow From Investing-691.1%-6,2661,060-12,92333,2302,641
Cashflow From Financing-72.1%27,06397,13471,73470,465143,057

Risks for URGN

What is the probability of a big loss on URGN?

99.6%


Probability that Urogen Pharma stock will be more than 20% underwater in next one year

98.1%


Probability that Urogen Pharma stock will be more than 30% underwater in next one year.

73.8%


Probability that Urogen Pharma stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does URGN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Urogen Pharma was unfortunately bought at previous high price.

Drawdowns

Returns for URGN

Cumulative Returns on URGN

-28.3%


5-Year Cumulative Returns

-23.4%


3-Year Cumulative Returns

What are the long-term rolling returns for URGN?

FIve years rolling returns for Urogen Pharma.

Annualized Returns

Which funds bought or sold URGN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-22
AMERIPRISE FINANCIAL INC
unchanged
-
30,504
748,504
-%
2023-05-18
JPMORGAN CHASE & CO
added
8,576
552,000
558,000
-%
2023-05-16
JANE STREET GROUP, LLC
new
-
784,199
784,199
-%
2023-05-16
SUSQUEHANNA INTERNATIONAL GROUP, LLP
added
411
1,497,080
1,842,760
-%
2023-05-15
LAZARD ASSET MANAGEMENT LLC
unchanged
-
1,000
28,000
-%
2023-05-15
683 Capital Management, LLC
reduced
-15.94
-24,937
175,560
0.01%
2023-05-15
FIRST MANHATTAN CO. LLC.
unchanged
-
370
9,240
-%
2023-05-15
MILLENNIUM MANAGEMENT LLC
added
27.96
819,000
3,278,000
-%
2023-05-15
STATE STREET CORP
reduced
-46.61
-886,495
1,110,850
-%
2023-05-15
Annandale Capital, LLC
unchanged
-
31,000
779,000
0.25%

1–10 of 43

Latest Funds Activity

Are funds buying URGN calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own URGN
No. of Funds

Urogen Pharma News

Best Stocks
Promising Preclinical Research on Allogeneic Gamma Delta CAR T ....
Best Stocks,
5 days ago
Seeking Alpha
InvestorsObserver
Seeking Alpha

Schedule 13G FIlings of Urogen Pharma

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
stonepine capital management, llc
5.7%
1,304,947
SC 13G/A
Dec 01, 2022
stonepine capital management, llc
5.2%
1,196,908
SC 13G
Jul 08, 2022
blackrock inc.
1.5%
340,412
SC 13G
Feb 14, 2022
wildcat capital management, llc
2.4%
533,139
SC 13G/A
Feb 14, 2022
credit suisse ag/
4.84%
1,085,749
SC 13G/A
Feb 04, 2022
wellington management group llp
1.06%
238,008
SC 13G/A
Feb 03, 2022
blackrock inc.
7.7%
1,728,094
SC 13G/A
Feb 12, 2021
credit suisse ag/
07%
1,121,071
SC 13G
Feb 12, 2021
wildcat capital management, llc
2.41%
533,139
SC 13G/A
Feb 11, 2021
menora mivtachim holdings ltd.
13.37%
2,954,699
SC 13G/A

URGN Fair Value

Urogen Pharma fair value in different scenarios

The table shows the Fair Value estimates for Urogen Pharma for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

-

-

1.82

-84.08%

4.00

-65.00%

12.28

7.44%
Current Inflation

-

-

-

-

0.21

-98.16%

3.00

-73.75%

10.11

-11.55%
Very High Inflation

-

-

-

-

0.75

-93.44%

1.83

-83.99%

7.57

-33.77%

Historical Urogen Pharma Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Urogen Pharma

View All Filings
Date Filed Form Type Document
May 11, 2023
8-K
Current Report
May 11, 2023
10-Q
Quarterly Report
May 01, 2023
10-K/A
Annual Report
Mar 24, 2023
10-K
Annual Report
Mar 22, 2023
8-K
Current Report
Feb 28, 2023
4/A
Insider Trading
Feb 28, 2023
4/A
Insider Trading
Feb 28, 2023
4
Insider Trading
Feb 13, 2023
SC 13G/A
Major Ownership Report

Latest Insider Trading transactions for URGN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-01-31
Schoenberg Mark
acquired
-
-
3,833
chief medical officer
2023-01-31
Barrett Elizabeth A.
acquired
-
-
18,333
chief executive officer
2023-01-31
Smith Jason Drew
sold
-16,556
10.12
-1,636
general counsel
2023-01-31
Schoenberg Mark
sold
-19,228
10.12
-1,900
chief medical officer
2023-01-31
Smith Jason Drew
acquired
-
-
3,333
general counsel
2023-01-20
Schoenberg Mark
acquired
613,385
5.00
122,677
chief medical officer
2022-10-31
Schoenberg Mark
acquired
-
-
500
chief medical officer
2022-10-31
Schoenberg Mark
sold
-3,057
11.85
-258
chief medical officer
2022-10-21
Nussbaum Ran
acquired
285,114
5.94
47,999
-

1–10 of 50

About Urogen Pharma

Elizabeth Barrett
200
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

URGN Income Statement

2023-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenue$ 17,192$ 13,564
Cost of revenue2,2651,525
Gross profit14,92712,039
Operating expenses:  
Research and development expenses12,49812,696
Selling, general and administrative expenses24,47421,300
Operating loss(22,045)(21,957)
Financing on prepaid forward obligation(5,224)(5,826)
Interest expense on long-term debt(3,553)(282)
Interest and other income (expense), net630(2)
Loss before income taxes(30,192)(28,067)
Income tax expense(21)(325)
Net Loss(30,213)(28,392)
Statements of Comprehensive Loss  
Net loss(30,213)(28,392)
Other comprehensive loss  
Unrealized gain (loss) on investments62(44)
Comprehensive Loss$ (30,151)$ (28,436)
Net loss per ordinary share - basic and diluted (in dollars per share)$ (1.30)$ (1.25)
Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share (in shares)23,279,95122,631,509

URGN Balance Sheet

2023-03-31
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 36,540$ 55,408
Marketable securities28,51444,556
Restricted cash814813
Accounts receivable12,49312,704
Inventories5,4664,325
Prepaid expenses and other current assets12,14611,101
Total current assets95,973128,907
Non-current assets:  
Property and equipment, net1,1031,297
Restricted deposit224223
Right of use assets2,3292,452
Marketable securities10,1650
Other non-current assets3,1602,740
Total Assets112,954135,619
Current liabilities:  
Accounts payable and accrued expenses17,13012,383
Employee related accrued expenses4,9198,257
Other current liabilities3,1853,276
Total current liabilities:25,23423,916
Non-current liabilities:  
Prepaid forward obligation101,91298,923
Long-term debt97,94197,537
Long-term lease liabilities1,4031,586
Uncertain tax positions liability3,0183,018
Total Liabilities229,508224,980
Commitments and Contingencies (Note 18)
Shareholders' Deficit:  
Ordinary shares, NIS 0.01 par value, 100,000,000 shares authorized at March 31, 2023 and December 31, 2022; 23,440,521 and 23,129,953 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively6463
Additional paid-in capital490,744487,787
Accumulated deficit(607,317)(577,104)
Accumulated other comprehensive loss(45)(107)
Total Shareholders' Deficit(116,554)(89,361)
Total Liabilities and Shareholders' Deficit$ 112,954$ 135,619